vs
Side-by-side financial comparison of STRATA Skin Sciences, Inc. (SSKN) and Village Farms International, Inc. (VFF). Click either name above to swap in a different company.
Village Farms International, Inc. is the larger business by last-quarter revenue ($12.2M vs $9.3M, roughly 1.3× STRATA Skin Sciences, Inc.). Village Farms International, Inc. runs the higher net margin — 19.9% vs 0.6%, a 19.3% gap on every dollar of revenue. On growth, Village Farms International, Inc. posted the faster year-over-year revenue change (31.5% vs -3.0%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
Grafton Village Cheese Company is a cheesemaker in the town of Grafton in the U.S. state of Vermont. The company produces hand-crafted aged cheddar cheese.
SSKN vs VFF — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.3M | $12.2M |
| Net Profit | $58.0K | $2.4M |
| Gross Margin | 61.8% | — |
| Operating Margin | 5.3% | — |
| Net Margin | 0.6% | 19.9% |
| Revenue YoY | -3.0% | 31.5% |
| Net Profit YoY | 101.3% | 128.2% |
| EPS (diluted) | $0.14 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.3M | $12.2M | ||
| Q3 25 | $6.9M | $66.7M | ||
| Q2 25 | $7.7M | $59.9M | ||
| Q1 25 | $6.8M | $77.1M | ||
| Q4 24 | $9.6M | — | ||
| Q3 24 | $8.8M | $54.9M | ||
| Q2 24 | $8.4M | $53.6M | ||
| Q1 24 | $6.8M | $78.1M |
| Q4 25 | $58.0K | $2.4M | ||
| Q3 25 | $-1.6M | $10.2M | ||
| Q2 25 | $-2.6M | $26.5M | ||
| Q1 25 | $-2.1M | $-6.7M | ||
| Q4 24 | $-4.6M | — | ||
| Q3 24 | $-2.1M | $-820.0K | ||
| Q2 24 | $-91.0K | $-23.5M | ||
| Q1 24 | $-3.4M | $-2.9M |
| Q4 25 | 61.8% | — | ||
| Q3 25 | 60.4% | 47.9% | ||
| Q2 25 | 56.2% | 37.3% | ||
| Q1 25 | 53.5% | 14.7% | ||
| Q4 24 | 61.4% | — | ||
| Q3 24 | 60.1% | 24.8% | ||
| Q2 24 | 59.0% | 25.4% | ||
| Q1 24 | 45.6% | 19.9% |
| Q4 25 | 5.3% | — | ||
| Q3 25 | -16.9% | 23.3% | ||
| Q2 25 | -30.1% | 20.8% | ||
| Q1 25 | -25.0% | -8.0% | ||
| Q4 24 | -44.7% | — | ||
| Q3 24 | -18.2% | 3.8% | ||
| Q2 24 | -5.7% | -43.5% | ||
| Q1 24 | -42.7% | -3.0% |
| Q4 25 | 0.6% | 19.9% | ||
| Q3 25 | -23.4% | 15.3% | ||
| Q2 25 | -33.6% | 44.2% | ||
| Q1 25 | -31.2% | -8.7% | ||
| Q4 24 | -47.6% | — | ||
| Q3 24 | -23.6% | -1.5% | ||
| Q2 24 | -1.1% | -43.9% | ||
| Q1 24 | -49.8% | -3.7% |
| Q4 25 | $0.14 | $0.01 | ||
| Q3 25 | $-0.36 | $0.08 | ||
| Q2 25 | $-0.62 | $0.24 | ||
| Q1 25 | $-0.51 | $-0.06 | ||
| Q4 24 | $-2.01 | — | ||
| Q3 24 | $-0.51 | $-0.01 | ||
| Q2 24 | $-0.03 | $-0.21 | ||
| Q1 24 | $-0.10 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.9M | $81.2M |
| Total DebtLower is stronger | $15.3M | $33.7M |
| Stockholders' EquityBook value | $2.9M | $299.9M |
| Total Assets | $30.5M | $423.1M |
| Debt / EquityLower = less leverage | 5.28× | 0.11× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.9M | $81.2M | ||
| Q3 25 | $7.1M | $82.6M | ||
| Q2 25 | $6.0M | $60.0M | ||
| Q1 25 | $6.5M | $15.1M | ||
| Q4 24 | $7.3M | — | ||
| Q3 24 | $7.1M | $28.7M | ||
| Q2 24 | $5.5M | $29.7M | ||
| Q1 24 | $5.2M | $26.7M |
| Q4 25 | $15.3M | $33.7M | ||
| Q3 25 | $15.3M | $34.6M | ||
| Q2 25 | $15.0M | $39.1M | ||
| Q1 25 | $15.0M | $39.2M | ||
| Q4 24 | $15.0M | — | ||
| Q3 24 | $15.0M | $43.3M | ||
| Q2 24 | $15.0M | $44.4M | ||
| Q1 24 | $15.0M | $46.1M |
| Q4 25 | $2.9M | $299.9M | ||
| Q3 25 | $1.3M | $295.4M | ||
| Q2 25 | $532.0K | $284.3M | ||
| Q1 25 | $3.0M | $248.3M | ||
| Q4 24 | $5.0M | — | ||
| Q3 24 | $9.4M | $274.4M | ||
| Q2 24 | $9.5M | $275.2M | ||
| Q1 24 | $9.4M | $296.2M |
| Q4 25 | $30.5M | $423.1M | ||
| Q3 25 | $30.7M | $418.4M | ||
| Q2 25 | $29.5M | $403.7M | ||
| Q1 25 | $33.0M | $377.1M | ||
| Q4 24 | $34.9M | — | ||
| Q3 24 | $39.4M | $417.8M | ||
| Q2 24 | $38.8M | $425.4M | ||
| Q1 24 | $39.2M | $458.4M |
| Q4 25 | 5.28× | 0.11× | ||
| Q3 25 | 11.65× | 0.12× | ||
| Q2 25 | 28.20× | 0.14× | ||
| Q1 25 | 5.04× | 0.16× | ||
| Q4 24 | 3.02× | — | ||
| Q3 24 | 1.60× | 0.16× | ||
| Q2 24 | 1.58× | 0.16× | ||
| Q1 24 | 1.59× | 0.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-239.0K | — |
| Free Cash FlowOCF − Capex | $-551.0K | — |
| FCF MarginFCF / Revenue | -5.9% | — |
| Capex IntensityCapex / Revenue | 3.4% | 90.8% |
| Cash ConversionOCF / Net Profit | -4.12× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-4.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-239.0K | — | ||
| Q3 25 | $-64.0K | $24.4M | ||
| Q2 25 | $-1.9M | — | ||
| Q1 25 | $-550.0K | $-6.4M | ||
| Q4 24 | $703.0K | — | ||
| Q3 24 | $-302.0K | $4.3M | ||
| Q2 24 | $591.0K | $5.7M | ||
| Q1 24 | $-804.0K | $-50.0K |
| Q4 25 | $-551.0K | — | ||
| Q3 25 | $-1.1M | $22.6M | ||
| Q2 25 | $-2.0M | — | ||
| Q1 25 | $-749.0K | $-8.9M | ||
| Q4 24 | $199.0K | — | ||
| Q3 24 | $-364.0K | $1.5M | ||
| Q2 24 | $246.0K | $4.8M | ||
| Q1 24 | $-1.5M | $-1.9M |
| Q4 25 | -5.9% | — | ||
| Q3 25 | -15.6% | 33.9% | ||
| Q2 25 | -26.1% | — | ||
| Q1 25 | -11.0% | -11.6% | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | -4.1% | 2.7% | ||
| Q2 24 | 2.9% | 9.0% | ||
| Q1 24 | -22.6% | -2.5% |
| Q4 25 | 3.4% | 90.8% | ||
| Q3 25 | 14.7% | 2.7% | ||
| Q2 25 | 0.8% | 4.6% | ||
| Q1 25 | 2.9% | 3.3% | ||
| Q4 24 | 5.3% | — | ||
| Q3 24 | 0.7% | 5.1% | ||
| Q2 24 | 4.1% | 1.6% | ||
| Q1 24 | 10.7% | 2.4% |
| Q4 25 | -4.12× | — | ||
| Q3 25 | — | 2.39× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
VFF
| International Sales | $8.7M | 71% |
| Cannabis United States Segment | $3.4M | 27% |
